NCT05203172
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MEK, RAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 4
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be receiving encorafenib/binimetinib & deriving clinical benefit
Exclusions: 
https://ClinicalTrials.gov/show/NCT05203172